Researchers from the University of Michigan are using a genetics program to alert cancer patients about the potential of a variant that puts someone at high risk of effects from chemotherapy. Daniel L. Hertz, Pharm.D., Ph.D., associate professor of pharmacy, discusses clinical treatment decisions and how evidence is showing how this testing can be effective.
